Sanofi Genzyme’s biologic medication ‘Dupixent (dupilumab),’ which was finally approved for reimbursement after a long wait, is creating a sensation in the market. After receiving approval for its reimbursement in severe atopic dermatitis last year, sales of Dupixent rose steeply to exceed 10 billion won in the first quarter this year. With the indication expanded to pediatric patients earlier this year, its sales growth is expected to accelerate further.

According to the market research institution IQVIA, sales of Dupixent recorded 13.5 billion won in the first quarter this year. This was a 306.2% YoY increase compared to the same quarter of the previous year, in which Dupixent recorded 3.3